How to Get NMN/NR (Nicotinamide Mononucleotide/Riboside) in Illinois

NMN vs. NR: Two Distinct Regulatory Paths in Illinois

NMN and NR both raise intracellular NAD+ levels, but they sit on opposite sides of a regulatory line that directly affects how you obtain them in Illinois. The FDA excluded NMN from the dietary supplement definition in November 2022, ruling that it had been investigated as a new drug before it was marketed as a supplement. NR was not subject to that exclusion.

This means NMN now requires a prescription and must be dispensed by a compounding pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act [1]. NR products such as ChromaDex's Tru Niagen (nicotinamide riboside chloride, 300 mg) remain available at retail pharmacies, health food stores, and online retailers across Illinois without a prescription.

The biological rationale for both compounds centers on restoring NAD+ pools that decline with age. Rajman et al. documented in a 2018 review that NAD+ levels fall by roughly 50% between ages 40 and 60 in multiple tissue types, contributing to mitochondrial dysfunction, impaired DNA repair, and metabolic decline 2. Both NMN and NR serve as biosynthetic precursors to NAD+, but they enter the salvage pathway at different enzymatic steps. NMN is converted directly to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNATs), while NR first requires phosphorylation by nicotinamide riboside kinases (NRK1/2) to become NMN before the same NMNAT-catalyzed step 3.

For Illinois residents, the practical takeaway is simple. If you want NR, buy it over the counter. If you want NMN, you need a prescriber and a compounding pharmacy.

How to Get a Compounded NMN Prescription in Illinois

Any Illinois-licensed prescriber with authority to write prescriptions can order compounded NMN. That starts with a clinical consultation, baseline laboratory work, and a written prescription sent to a 503A compounding pharmacy.

Step 1: Clinical consultation. Schedule an appointment with an MD, DO, NP, or PA licensed in Illinois. Nurse practitioners in Illinois hold full practice authority under the Nurse Practice Act (225 ILCS 65), meaning they can prescribe independently without a collaborative agreement after 4 to 000 hours of supervised practice. PAs require a written collaborative agreement with a supervising physician.

Step 2: Baseline labs. Most longevity-focused clinicians order a panel that includes a comprehensive metabolic panel (CMP), complete blood count (CBC), fasting lipid panel, fasting insulin, hemoglobin A1c, and liver function tests (ALT, AST). Some specialty practices also test whole-blood NAD+ levels or urinary methylation metabolites, though these are not standardized.

Step 3: Prescription. Typical starting doses range from 250 mg to 500 mg once daily as an oral capsule or sublingual tablet. Yoshino et al. used 250 mg/day orally in their 2021 randomized controlled trial (N=25 postmenopausal women with prediabetes) and demonstrated increased skeletal muscle insulin signaling and insulin sensitivity after 10 weeks of supplementation 4.

Step 4: Pharmacy fulfillment. The prescriber sends the script to a 503A compounding pharmacy. Illinois-based compounders can fill it directly. Out-of-state 503A pharmacies may also ship to Illinois addresses, provided they hold the appropriate nonresident pharmacy license from the Illinois Department of Financial and Professional Regulation (IDFPR).

Telehealth Prescribing for NMN in Illinois

Illinois fully supports telehealth prescribing for NMN. The state's Telehealth Act (Public Act 102-0104) allows licensed prescribers to establish a valid prescriber-patient relationship via synchronous audio-video consultation. No in-person visit is required for an initial NMN prescription.

Here is what a typical telehealth workflow looks like for an Illinois resident seeking compounded NMN:

1. Select a telehealth provider licensed in Illinois that offers longevity or NAD+ optimization protocols.
2. Complete intake forms that cover medical history, current medications, supplement use, and treatment goals.
3. Upload or order labs. Some telehealth platforms partner with national lab networks (Quest Diagnostics, Labcorp) and will order the draw directly. Others accept recent lab work (within 60 to 90 days) uploaded through their patient portal.
4. Attend the video consultation. Expect 15 to 30 minutes. The clinician reviews your labs, discusses risks and expected outcomes, and determines whether NMN is appropriate.
5. Receive your prescription electronically at the compounding pharmacy of your choice.

Illinois does not impose a separate prescribing schedule or formulary restriction on compounded NMN through telehealth channels. The same prescriptive authority that applies in an office visit applies over video. Refills can also be managed entirely through telehealth follow-ups, which most providers schedule every 3 to 6 months.

One caveat: the DEA's post-pandemic telehealth prescribing flexibility applies to controlled substances, but NMN is not a controlled substance. The standard Illinois telehealth framework is all that governs NMN prescribing.

503A Compounding Pharmacies Serving Illinois

Section 503A of the FD&C Act permits licensed pharmacies to compound patient-specific preparations from bulk drug substances when they receive a valid individual prescription 1. These pharmacies do not need FDA pre-market approval for each formulation, but they must comply with United States Pharmacopeia (USP) chapters 795 (nonsterile compounding) and 797 (sterile compounding, if applicable).

Illinois has multiple 503A pharmacies capable of compounding NMN. The IDFPR maintains a public license lookup at idfpr.illinois.gov where patients can verify any pharmacy's active status and disciplinary history. Out-of-state compounders shipping to Illinois must hold a nonresident pharmacy license issued by IDFPR.

Common NMN formulations available through 503A pharmacies:

• Oral capsules: 125 mg, 250 mg, or 500 mg per capsule
• Sublingual tablets: 125 mg or 250 mg (designed for buccal absorption, bypassing first-pass hepatic metabolism)
• Sublingual troches: 250 mg (compounded with a flavoring base)

Pricing varies by pharmacy and formulation. Expect to pay between $60 and $150 for a 30-day supply of 250 mg to 500 mg daily, depending on the form and the specific compounder. Sublingual formulations tend to cost 20% to 40% more than standard oral capsules due to additional compounding steps.

Shipping timelines from compounding pharmacies to Illinois addresses typically range from 5 to 10 business days after the pharmacy receives and verifies the prescription. Some pharmacies offer expedited 2- to 3-day shipping for an additional fee.

What Labs Should You Get Before Starting NMN?

A pre-treatment lab panel serves two purposes: establishing a metabolic baseline and screening for contraindications. There is no FDA-mandated lab protocol for NMN, but clinicians specializing in NAD+ optimization commonly order the following.

Standard baseline panel:

• Comprehensive metabolic panel (CMP) including glucose, creatinine, BUN, and electrolytes
• Hepatic function: ALT, AST, alkaline phosphatase, total bilirubin
• Complete blood count with differential
• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Fasting insulin and hemoglobin A1c
• Vitamin D (25-hydroxyvitamin D)

Optional advanced biomarkers:

• Whole-blood or intracellular NAD+ levels (offered by specialty labs such as Jinfiniti Precision Medicine)
• Homocysteine (as a marker of methylation demand, since NAD+ metabolism consumes methyl groups)
• High-sensitivity C-reactive protein (hs-CRP)
• GlycanAge or other biological age markers (used in research settings but not yet validated for clinical decision-making)

Martens et al. measured NAD+ metabolites via targeted mass spectrometry in their 2018 crossover trial of NR supplementation (N=24, healthy adults aged 55 to 79) and found that 1 to 000 mg/day NR for 6 weeks raised whole-blood NAD+ by 60% above baseline 5. This trial also showed a trend toward reduced systolic blood pressure (by a mean of 5.5 mmHg) and reduced aortic stiffness, though neither endpoint reached statistical significance in this small sample.

Follow-up labs are typically drawn at 8 to 12 weeks post-initiation and then every 6 months. The primary monitoring targets are hepatic transaminases (to screen for any liver stress) and metabolic markers (glucose, insulin, lipids) to track treatment response.

Illinois Medicaid and Insurance Coverage for NMN

Compounded medications occupy an unusual space in insurance coverage. Most commercial insurers in Illinois do not cover compounded NMN because it lacks FDA approval as a finished drug product. Out-of-pocket payment is the norm.

Illinois Medicaid (administered through the Illinois Department of Healthcare and Family Services) may cover compounded NMN with prior authorization (PA) for specific clinical indications, though approval is not guaranteed and depends on the individual case. The PA process requires the prescribing clinician to submit documentation demonstrating medical necessity, which typically includes:

• A letter of medical necessity from the prescriber
• Supporting laboratory results (e.g., documented NAD+ deficiency or metabolic dysfunction)
• Evidence that the patient has tried and failed standard treatments for the underlying condition
• A peer-reviewed citation supporting NMN use for the specific indication

The PA review timeline in Illinois Medicaid is 24 hours for urgent requests and 5 business days for standard requests, per Illinois Administrative Code Title 89, Section 140.40.

For patients paying out of pocket, some health savings accounts (HSAs) and flexible spending accounts (FSAs) will reimburse compounded NMN if the patient has a valid prescription and a letter of medical necessity. Check with your HSA/FSA administrator, as policies vary by plan.

Safety Profile and Known Side Effects

Human trial data on NMN remains limited but generally favorable at doses up to 1 to 250 mg/day. The most commonly reported side effects in published trials have been mild and self-limiting.

A phase I dose-escalation study by Igarashi et al. (2022) administered single oral doses of NMN at 100, 250, and 500 mg to 30 healthy Japanese men. No serious adverse events occurred at any dose level, and all safety laboratory values remained within normal limits 6. A separate 12-week trial by Yi et al. (2023, N=80 middle-aged adults) found that 300 mg, 600 mg, and 900 mg daily NMN were all well tolerated, with no significant differences in adverse events between NMN and placebo groups 7.

For NR, the safety dataset is slightly larger. Conze et al. (2019) conducted an 8-week dose-escalation study (N=140) evaluating NR chloride at doses up to 1 to 000 mg twice daily (2 to 000 mg/day total). The no-observed-adverse-effect level (NOAEL) was established at 300 mg/kg/day in preclinical models, and no clinically meaningful adverse events were observed at any human dose tested 8.

Reported side effects across trials include:

• Mild gastrointestinal discomfort (nausea, bloating) in approximately 10% to 15% of participants
• Transient flushing (more common with higher doses)
• Headache (reported at similar rates in treatment and placebo groups)
• Skin itching (rare, reported in fewer than 3% of NR trial participants)

No hepatotoxicity, nephrotoxicity, or hematologic abnormalities have been reported in any published human NMN or NR trial to date.

Who Should Not Take NMN or NR

Not every patient is a candidate. Contraindications and cautions include active malignancy (NAD+ fuels cancer cell metabolism through NAMPT overexpression, as described by Garten et al. in the International Journal of Molecular Sciences 9), pregnancy, lactation, and age under 18 (due to absent pediatric safety data).

Patients on anticoagulants or antiplatelet agents should inform their prescriber, as one preclinical study noted NMN's effects on platelet function, though no clinically significant bleeding events have been reported in humans.

Patients with active liver disease should undergo more frequent hepatic monitoring (every 4 to 6 weeks rather than every 8 to 12 weeks) during the initial treatment period.

What to Expect After Starting NMN in Illinois

Setting realistic expectations matters. NMN is not a drug with an immediate, perceptible onset of action like a stimulant or analgesic. Changes in NAD+ levels occur within days of starting supplementation (Trammell et al. documented a 2.7-fold increase in NAD+ metabolites within 8 hours of a single 1 to 000 mg oral dose of NR 10), but subjective improvements in energy, sleep quality, and exercise recovery typically take 2 to 8 weeks to manifest, based on patient-reported outcomes in published trials.

Objective markers such as fasting insulin, blood pressure, and lipid profiles should be reassessed at the 8- to 12-week mark. The Yoshino et al. trial [4] detected improvements in muscle insulin sensitivity at 10 weeks on 250 mg/day, providing a reasonable timeframe for initial reassessment.

Dose adjustments are common. Many clinicians start at 250 mg/day and titrate to 500 mg/day after 4 to 6 weeks if the patient tolerates the lower dose and lab values remain stable.